Cargando…
Epidemiology and Survival outcomes of HIV-associated cervical cancer in Nigeria
INTRODUCTION: Invasive cervical cancer (ICC) is an HIV-associated cancer that is preventable and precancerous stages including early ICC stages could be detected through screening offering opportunities for treatment and cure. The high incidence in women living with HIV and late presentation often a...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cold Spring Harbor Laboratory
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10441483/ https://www.ncbi.nlm.nih.gov/pubmed/37609183 http://dx.doi.org/10.1101/2023.08.08.23293820 |
_version_ | 1785093383941783552 |
---|---|
author | Musa, Jonah Kocherginsky, Masha Magaji, Francis A. Maryam, Ali J. Asufi, Joyce Nenrot, Danjuma Burdett, Kristen Katam, Neelima Christian, Elizabeth N. Palanisamy, Nisha Odukoya, Olukemi Silas, Olugbenga A. Abdulkareem, Fatimah Akpa, Philip Badmos, Kabir Imade, Godwin E. Akanmu, Alani S. Gursel, Demirkan B. Zheng, Yinan Joyce, Brian T. Achenbach, Chad J. Sagay, Atiene S. Anorlu, Rose Wei, Jian-Jun Ogunsola, Folasade Murphy, Robert L. Hou, Lifang Simon, Melissa A. |
author_facet | Musa, Jonah Kocherginsky, Masha Magaji, Francis A. Maryam, Ali J. Asufi, Joyce Nenrot, Danjuma Burdett, Kristen Katam, Neelima Christian, Elizabeth N. Palanisamy, Nisha Odukoya, Olukemi Silas, Olugbenga A. Abdulkareem, Fatimah Akpa, Philip Badmos, Kabir Imade, Godwin E. Akanmu, Alani S. Gursel, Demirkan B. Zheng, Yinan Joyce, Brian T. Achenbach, Chad J. Sagay, Atiene S. Anorlu, Rose Wei, Jian-Jun Ogunsola, Folasade Murphy, Robert L. Hou, Lifang Simon, Melissa A. |
author_sort | Musa, Jonah |
collection | PubMed |
description | INTRODUCTION: Invasive cervical cancer (ICC) is an HIV-associated cancer that is preventable and precancerous stages including early ICC stages could be detected through screening offering opportunities for treatment and cure. The high incidence in women living with HIV and late presentation often at advanced stages of ICC with limited treatment facilities often result in early mortality. We sought to compare the epidemiologic characteristics and survival differences in HIV status of ICC patients in Nigeria. METHODS: We conducted a cohort study at two federal academic hospital-based research sites in Jos University Teaching Hospital, and Lagos University Teaching Hospital Nigeria, between March 2018 and September 2022. We enrolled women with histologically confirmed ICC with known HIV status, and FIGO staging as part of the United States of America’s National Institutes of Health/National Cancer Institute funded project titled ‘Epigenomic Biomarkers of HIV-Associated Cancers in Nigeria’. The primary outcome was all-cause mortality with assessment of overall survival (OS) and time to death after ICC diagnosis. OS distribution was estimated using the method of Kaplan-Meier and compared between groups using the log-rank test. RESULTS: A total of 239 women with confirmed ICC were enrolled and included in this analysis, of whom 192 (80.3%) were HIV-negative (HIV-/ICC+), and 47 (19.7%) were HIV-positive (HIV+/ICC+). The HIV+/ICC) patients were younger with median age 46 (IQR: 40–51) years compared to 57 (IQR: 45–66) among HIV-/ICC+) (P<0.001. Squamous cell carcinoma was the commonest histopathologic variant in 80.4% of ICC diagnosis, moderately differentiated tumor grade in 68.1% in both groups. HIV+/ICC+ diagnosis was at FIGO advanced stages in 64.9% compared to 47.9% in HIV-/ICC+. The HIV-/ICC+ women had better OS compared to HIV+/ICC+ participants (p=0.018), with 12-month OS 84.1% (95%CI: 75% - 90%) and 67.6% (95%CI: 42%−84%) respectively. CONCLUSION: ICC is diagnosed at a relatively young age in women living with HIV, with a significantly lower overall survival probability compared to women without HIV. The trend of presentation and diagnosis at advanced stages in women living with HIV could partly explain the differences in overall survival. |
format | Online Article Text |
id | pubmed-10441483 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Cold Spring Harbor Laboratory |
record_format | MEDLINE/PubMed |
spelling | pubmed-104414832023-08-22 Epidemiology and Survival outcomes of HIV-associated cervical cancer in Nigeria Musa, Jonah Kocherginsky, Masha Magaji, Francis A. Maryam, Ali J. Asufi, Joyce Nenrot, Danjuma Burdett, Kristen Katam, Neelima Christian, Elizabeth N. Palanisamy, Nisha Odukoya, Olukemi Silas, Olugbenga A. Abdulkareem, Fatimah Akpa, Philip Badmos, Kabir Imade, Godwin E. Akanmu, Alani S. Gursel, Demirkan B. Zheng, Yinan Joyce, Brian T. Achenbach, Chad J. Sagay, Atiene S. Anorlu, Rose Wei, Jian-Jun Ogunsola, Folasade Murphy, Robert L. Hou, Lifang Simon, Melissa A. medRxiv Article INTRODUCTION: Invasive cervical cancer (ICC) is an HIV-associated cancer that is preventable and precancerous stages including early ICC stages could be detected through screening offering opportunities for treatment and cure. The high incidence in women living with HIV and late presentation often at advanced stages of ICC with limited treatment facilities often result in early mortality. We sought to compare the epidemiologic characteristics and survival differences in HIV status of ICC patients in Nigeria. METHODS: We conducted a cohort study at two federal academic hospital-based research sites in Jos University Teaching Hospital, and Lagos University Teaching Hospital Nigeria, between March 2018 and September 2022. We enrolled women with histologically confirmed ICC with known HIV status, and FIGO staging as part of the United States of America’s National Institutes of Health/National Cancer Institute funded project titled ‘Epigenomic Biomarkers of HIV-Associated Cancers in Nigeria’. The primary outcome was all-cause mortality with assessment of overall survival (OS) and time to death after ICC diagnosis. OS distribution was estimated using the method of Kaplan-Meier and compared between groups using the log-rank test. RESULTS: A total of 239 women with confirmed ICC were enrolled and included in this analysis, of whom 192 (80.3%) were HIV-negative (HIV-/ICC+), and 47 (19.7%) were HIV-positive (HIV+/ICC+). The HIV+/ICC) patients were younger with median age 46 (IQR: 40–51) years compared to 57 (IQR: 45–66) among HIV-/ICC+) (P<0.001. Squamous cell carcinoma was the commonest histopathologic variant in 80.4% of ICC diagnosis, moderately differentiated tumor grade in 68.1% in both groups. HIV+/ICC+ diagnosis was at FIGO advanced stages in 64.9% compared to 47.9% in HIV-/ICC+. The HIV-/ICC+ women had better OS compared to HIV+/ICC+ participants (p=0.018), with 12-month OS 84.1% (95%CI: 75% - 90%) and 67.6% (95%CI: 42%−84%) respectively. CONCLUSION: ICC is diagnosed at a relatively young age in women living with HIV, with a significantly lower overall survival probability compared to women without HIV. The trend of presentation and diagnosis at advanced stages in women living with HIV could partly explain the differences in overall survival. Cold Spring Harbor Laboratory 2023-08-13 /pmc/articles/PMC10441483/ /pubmed/37609183 http://dx.doi.org/10.1101/2023.08.08.23293820 Text en https://creativecommons.org/licenses/by/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/) , which allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, so long as attribution is given to the creator. The license allows for commercial use. |
spellingShingle | Article Musa, Jonah Kocherginsky, Masha Magaji, Francis A. Maryam, Ali J. Asufi, Joyce Nenrot, Danjuma Burdett, Kristen Katam, Neelima Christian, Elizabeth N. Palanisamy, Nisha Odukoya, Olukemi Silas, Olugbenga A. Abdulkareem, Fatimah Akpa, Philip Badmos, Kabir Imade, Godwin E. Akanmu, Alani S. Gursel, Demirkan B. Zheng, Yinan Joyce, Brian T. Achenbach, Chad J. Sagay, Atiene S. Anorlu, Rose Wei, Jian-Jun Ogunsola, Folasade Murphy, Robert L. Hou, Lifang Simon, Melissa A. Epidemiology and Survival outcomes of HIV-associated cervical cancer in Nigeria |
title | Epidemiology and Survival outcomes of HIV-associated cervical cancer in Nigeria |
title_full | Epidemiology and Survival outcomes of HIV-associated cervical cancer in Nigeria |
title_fullStr | Epidemiology and Survival outcomes of HIV-associated cervical cancer in Nigeria |
title_full_unstemmed | Epidemiology and Survival outcomes of HIV-associated cervical cancer in Nigeria |
title_short | Epidemiology and Survival outcomes of HIV-associated cervical cancer in Nigeria |
title_sort | epidemiology and survival outcomes of hiv-associated cervical cancer in nigeria |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10441483/ https://www.ncbi.nlm.nih.gov/pubmed/37609183 http://dx.doi.org/10.1101/2023.08.08.23293820 |
work_keys_str_mv | AT musajonah epidemiologyandsurvivaloutcomesofhivassociatedcervicalcancerinnigeria AT kocherginskymasha epidemiologyandsurvivaloutcomesofhivassociatedcervicalcancerinnigeria AT magajifrancisa epidemiologyandsurvivaloutcomesofhivassociatedcervicalcancerinnigeria AT maryamalij epidemiologyandsurvivaloutcomesofhivassociatedcervicalcancerinnigeria AT asufijoyce epidemiologyandsurvivaloutcomesofhivassociatedcervicalcancerinnigeria AT nenrotdanjuma epidemiologyandsurvivaloutcomesofhivassociatedcervicalcancerinnigeria AT burdettkristen epidemiologyandsurvivaloutcomesofhivassociatedcervicalcancerinnigeria AT katamneelima epidemiologyandsurvivaloutcomesofhivassociatedcervicalcancerinnigeria AT christianelizabethn epidemiologyandsurvivaloutcomesofhivassociatedcervicalcancerinnigeria AT palanisamynisha epidemiologyandsurvivaloutcomesofhivassociatedcervicalcancerinnigeria AT odukoyaolukemi epidemiologyandsurvivaloutcomesofhivassociatedcervicalcancerinnigeria AT silasolugbengaa epidemiologyandsurvivaloutcomesofhivassociatedcervicalcancerinnigeria AT abdulkareemfatimah epidemiologyandsurvivaloutcomesofhivassociatedcervicalcancerinnigeria AT akpaphilip epidemiologyandsurvivaloutcomesofhivassociatedcervicalcancerinnigeria AT badmoskabir epidemiologyandsurvivaloutcomesofhivassociatedcervicalcancerinnigeria AT imadegodwine epidemiologyandsurvivaloutcomesofhivassociatedcervicalcancerinnigeria AT akanmualanis epidemiologyandsurvivaloutcomesofhivassociatedcervicalcancerinnigeria AT gurseldemirkanb epidemiologyandsurvivaloutcomesofhivassociatedcervicalcancerinnigeria AT zhengyinan epidemiologyandsurvivaloutcomesofhivassociatedcervicalcancerinnigeria AT joycebriant epidemiologyandsurvivaloutcomesofhivassociatedcervicalcancerinnigeria AT achenbachchadj epidemiologyandsurvivaloutcomesofhivassociatedcervicalcancerinnigeria AT sagayatienes epidemiologyandsurvivaloutcomesofhivassociatedcervicalcancerinnigeria AT anorlurose epidemiologyandsurvivaloutcomesofhivassociatedcervicalcancerinnigeria AT weijianjun epidemiologyandsurvivaloutcomesofhivassociatedcervicalcancerinnigeria AT ogunsolafolasade epidemiologyandsurvivaloutcomesofhivassociatedcervicalcancerinnigeria AT murphyrobertl epidemiologyandsurvivaloutcomesofhivassociatedcervicalcancerinnigeria AT houlifang epidemiologyandsurvivaloutcomesofhivassociatedcervicalcancerinnigeria AT simonmelissaa epidemiologyandsurvivaloutcomesofhivassociatedcervicalcancerinnigeria |